H.C. Wainwright Raises Immunovant Target to $40 on RA Trial Data

H.C. Wainwright raised its price target on Immunovant (IMVT) to $40 from $35, maintaining a Buy rating after the company reported positive Phase 2 trial data for its rheumatoid arthritis treatment.

The trial demonstrated high response rates among patients, including those who had previously been treated with multiple advanced therapies such as JAK inhibitors. According to H.C. Wainwright, this suggests that FcRn inhibition works through a different mechanism than JAK/TNF-directed treatments, potentially offering a new option for patients who have failed other therapies. The analyst noted that response rates in rheumatoid arthritis often decline as patients cycle through various medications, making the sustained efficacy particularly noteworthy.

For traders, the upgrade signals growing confidence in Immunovant's pipeline and could attract further institutional interest. The stock may see increased volatility as the market digests the implications of the data for future regulatory filings and commercial potential. Traders can monitor real-time price movements and volume on NowPrice's live equities dashboard to track market reaction.

Looking ahead, investors will watch for additional data from ongoing trials and any updates on the regulatory pathway. The company may also provide further details on its development timeline for FcRn inhibitors in other autoimmune indications. H.C. Wainwright's revised target implies roughly 14% upside from the previous target, reflecting optimism about the drug's differentiation and market opportunity.